Abionyx Pharma jumps on new CER-001 results in kidney disease

Abionyx Pharma SA

15/11/2021 08:57

** Shares in Abionyx Pharma  ABNX.PA  jump 5.6% after the
French biopharmaceutical company posted new positive clinical
results in kidney disease associated with lecithin-cholesterol
acyltransferase (LCAT) deficiency 
    ** Results demonstrate that CER-001 has the potential to be
beneficial in other renal diseases characterized by renal lipid
deposits, the company says  urn:newsml:reuters.com:*:nFWN2S60RX
    ** According to Midcap Partners this could constitute new
therapeutic areas for the group beyond this rare orphan disease
for which it obtained orphan drug status last October
    ** "To date, the group has already produced sufficiently
remarkable results to interest specialists in the field of liver
diseases, in the ophthalmic field, and now to advance in a
registration process as an orphan disease", the brokerage adds
    ** Abionyx's shares have gained more than 60% over the last
month

 (Reporting by Kate Entringer)
 ((kate.entringer@thomsonreuters.com))